Due to the extremely contagious nature of SARS-COV-2, it presents a significant threat to humans
worldwide. A plethora of studies are going on all over the world to discover the drug to fight SARS-COV-2. One
of the most promising targets is RNA-dependent RNA polymerase (RdRp), responsible for viral RNA replication
in host cells. Since RdRp is a viral enzyme with no host cell homologs, it allows the development of selective
SARS-COV-2 RdRp inhibitors. A variety of studies used in silico approaches for virtual screening, molecular
docking, and repurposing of already existing drugs and phytochemicals against SARS-COV-2 RdRp. This review
focuses on collating compounds possessing the potential to inhibit SARS-COV-2 RdRp based on in silico studies
to give medicinal chemists food for thought so that the existing drugs can be repurposed for the control and treatment
of ongoing COVID-19 pandemic after performing in vitro and in vivo experiments.
Keywords: COVID-19, SARS-COV-2, in silico, molecular docking, RdRp, RNA-dependent RNA polymerase.
Rights & PermissionsPrintExport